Prilosec switch
This article was originally published in The Tan Sheet
Executive Summary
Status of Astra Merck agreement with Procter & Gamble for the Rx-to-OTC switch of the proton pump inhibitor omeprazole is one issue posed by the possible dissolution of the joint venture reportedly under discussion between the Swedish company and Merck. The agreement with P&G was announced in December ("The Tan Sheet" Dec. 22, 1997, p. 2). By exiting the joint venture now, Merck could replace the revenue stream from Prilosec with break-up fees from Astra. For Astra, exiting the joint venture would give the company the freedom to pursue a strategic move without the hindrance of the U.S. licensing agreement to the Merck joint venture...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning